LIALDA
LOE ApproachingNDAORALTABLET, DELAYED RELEASE
Approved
Jan 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
LIALDA by Takeda is understood, but it appears to have a topical anti-inflammatory effect on the colonic epithelial cells. First approved in 2007.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIALDA is an oral delayed-release tablet formulation of mesalamine, an aminosalicylate used to treat ulcerative colitis and maintain remission in inflammatory bowel disease. The drug works through local anti-inflammatory action in the colon. It represents a small-molecule therapeutic approach to managing chronic gastrointestinal inflammation.
$14MPart D
LOE ApproachingProduct is in late-stage commercialization with modest Part D penetration; expect smaller team focus on retention rather than aggressive expansion.
Mechanism of Action
understood, but it appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with ulcerative colitis, and it is possible that mesalamine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIALDA roles focus on commercial execution and market access in a competitive, consolidating therapeutic area. Positions emphasize retention of market share against generics and newer therapies rather than growth-stage responsibilities.
Brand Manager
Worked on LIALDA at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.